This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Valeant Pharmaceuticals International, Inc.
Drug Names(s): bexarotene capsules, LGD1069
Description: BioMedTracker has separate entries for Targretin capsules and gel. For additional information, please see Targretin gel.
Targretin consists of bexarotene, a retinoid that selectively activate retinoid X receptors (RXRs). RXRs regulate numerous cell activities including cell cycling, proliferation, and apoptosis.
Deal Structure: Revenue splits for this drug are BioMedTracker estimates.
Lilly and Ligand
In October 1997, Ligand and Eli Lilly entered into a strategic alliance under which Lilly received rights to Targretin capsules. In February 1999, Ligand recaptured all rights to Targretin capsules as Lilly decided not to proceed with its development.
Ferrer and Ligand
In March 1999, Ligand signed marketing and distribution agreements with Ferrer Internacional, S.A. to exclusively market and distribute ONTAK, Panretin gel, Panretin capsules, Targretin gel and Targretin capsules, in Spain, Portugal, Greece, and Central and South America.
Alfa Wassermann and Ligand
In January 2000, Ligand signed a marketing and distribution agreement with Alfa Wassermann S.p.A. to exclusively market and distribute in Italy ONTAK, Panretin gel, Panretin capsules, Targretin gel and Targretin capsules. Ligand received from Alfa Wassermann, as reimbursement for certain registration services...See full deal structure in Biomedtracker
Partners: Grupo Ferrer Internacional, S.A. Alfa Wassermann SpA Royalty Pharma AG Teva Pharmaceutical Industries Ltd. Minophagen Pharmaceutical Co., Ltd. Eisai Co., Ltd.
Targretin capsules News
Pink Sheet Ligand Targretin gel
Additional information available to subscribers only: